WallStSmart
CTXR

Citius Pharmaceuticals Inc

NASDAQ: CTXR · HEALTHCARE · BIOTECHNOLOGY

$0.70
+16.96% today

Updated 2026-04-30

Market cap
$17.23M
P/E ratio
P/S ratio
4.37x
EPS (TTM)
$-2.46
Dividend yield
52W range
$1 – $2
Volume
0.7M

Citius Pharmaceuticals Inc (CTXR) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
1 of 8
Last 8 quarters
Avg EPS surprise
-156.7%
Last 4 quarters
Revenue YoY growth
+2429.5%
Most recent quarter
EPS YoY growth
+70.8%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-15.1%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-23.8%
2025-12-23
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-13$-0.38-26.7%$0.79$0.74-6.5%
2025-12-23$-0.46-1020.0%$1.05$0.80-23.8%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.30$-0.38-26.7%$3.94M+2429.5%
2025-09-30$0.05$-0.46-1020.0%
2025-06-30$0.05$-0.80-1700.0%
2025-03-31$0.11$-1.27-1254.5%
2024-12-31$-1.25$-1.30-4.0%$155926.00
2024-09-30$-0.04$-1.59-3872.5%$155926.00
2024-06-30$-0.05$-0.06-20.0%
2024-03-31$-0.06$-0.05+16.7%
2023-12-31$0.13$-0.06-146.2%
2023-09-30$-0.02$-0.08-300.0%
2023-06-30$-0.05$-0.06-20.0%
2023-03-31$-0.04$-0.07-75.0%

Frequently asked questions

Has Citius Pharmaceuticals Inc beaten earnings estimates?
Citius Pharmaceuticals Inc has beaten Wall Street EPS estimates in 1 of its last 8 quarterly reports, with an average EPS surprise of -156.7% over the last 4 quarters.
How does CTXR stock react to earnings?
CTXR stock has moved an average of -15.1% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Citius Pharmaceuticals Inc's revenue growth rate?
Citius Pharmaceuticals Inc reported year-over-year revenue growth of +2429.5% in its most recent quarter, with EPS growing +70.8% year-over-year.